Core Viewpoint - Quest Diagnostics has announced a 7.5% increase in its quarterly cash dividend to $0.86 per share, effective April 20, 2026, with an annual cash dividend totaling $3.44 per share [1] Group 1: Dividend Increase - The Board of Directors has authorized a 7.5% increase in the quarterly cash dividend from $0.80 to $0.86 per share [1] - The increase will be effective for the dividend payable on April 20, 2026, to shareholders of record on April 6, 2026 [1] - The annual cash dividend will now amount to $3.44 per share [1] Group 2: Share Repurchase Authorization - The Board of Directors has increased the Company's share repurchase authorization by $1 billion [2] - This increase is in addition to the approximately $0.4 billion that was available as of December 31, 2025, under the share repurchase program [2] Group 3: Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, connecting clinicians and consumers with laboratory insights [3] - The company serves half of the physicians and hospitals in the United States and one in three American adults each year [3] - Quest Diagnostics employs nearly 57,000 individuals to deliver diagnostic insights that inspire actions to improve health [3]

Core Viewpoint - Quest Diagnostics Incorporated will report its fourth quarter and full year 2025 financial results on February 10, 2026, before market opens [1] Group 1: Financial Reporting - The quarterly conference call to discuss the financial results will begin at 8:30 a.m. Eastern Time on February 10, 2026 [1] - Access to the conference call can be made by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode "7895081" [2] - A replay of the call will be available online and by phone from February 10, 2026, until February 24, 2026 [3] Group 2: Company Overview - Quest Diagnostics operates within the healthcare ecosystem, providing diagnostic insights to improve health outcomes [5] - The company serves one in three adult Americans and half of the physicians and hospitals in the U.S. [5] - Quest Diagnostics employs over 55,000 individuals, emphasizing the transformative potential of their diagnostic insights [5]

Core Insights - Quest Diagnostics will present its strategy, performance, and market trends at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [1] - The presentation will be available via live webcast and archived for later access [2] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. [3] - The company aims to improve health outcomes through diagnostic insights derived from a large database of clinical lab results [3] - With over 55,000 employees, Quest Diagnostics focuses on transforming lives and creating a healthier world through its services [3]

Core Viewpoint - Quest Diagnostics has shown a positive performance in its stock price, outperforming the S&P 500, but there are questions about whether this trend will continue leading up to the next earnings release [1] Financial Performance - Quest Diagnostics reported Q3 2025 adjusted earnings per share (EPS) of $2.60, exceeding the Zacks Consensus Estimate by 3.59% and up 13% from the previous year [2] - The company's GAAP earnings were $2.16 per share, reflecting an 8.5% increase year-over-year [3] - Revenues for Q3 rose 15.2% year-over-year to $2.82 billion, surpassing the Zacks Consensus Estimate by 3.45% [4] - Diagnostic Information Services revenues increased by 13.5% year-over-year to $2.76 billion, exceeding projections [4] - Volumes measured by requisitions were up 12.5% year-over-year, with revenue per requisition increasing by 0.8% [5] Margin Analysis - The cost of services in Q3 was $1.87 billion, up 11.3% year-over-year, while gross profit rose 17% to $949 million [6] - The gross margin improved to 33.7%, an increase of 110 basis points [6] - SG&A expenses totaled $501 million, up 11.8% from the previous year, with an adjusted operating margin of 15.9%, representing a 132-basis point expansion [6] Financial Position - At the end of Q3 2025, Quest Diagnostics had cash and cash equivalents of $432 million, up from $319 million at the end of Q2 [7] - The cumulative net cash provided by operating activities was $1.42 billion, compared to $858 million a year ago [7] - The company has a five-year annualized dividend growth rate of 7.21% [7] Guidance - Quest Diagnostics updated its full-year 2025 revenue outlook to a range of $10.96-$11.00 billion, indicating a year-over-year increase of 11-11.4% [8] - Adjusted EPS is expected to be in the range of $9.76-$9.84, up from previous estimates [8] Market Sentiment - There has been a downward trend in estimates revision for the stock over the past month [10] - Quest Diagnostics holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [12] - The company has a Growth Score of B, a Momentum Score of F, and a Value Score of B, placing it in the top 40% for value investors [11]

Core Points - Quest Diagnostics will report its third quarter 2025 financial results on October 21, 2025, before market opens [1] - A conference call to discuss the results will take place at 8:30 a.m. Eastern Time on the same day [1] - The call can be accessed via specific phone numbers for domestic and international participants [2] Financial Reporting Details - The earnings release and live webcast will be available on the company's investor website [2] - A replay of the call will be accessible online and via phone from October 21, 2025, until November 5, 2025 [3] Company Overview - Quest Diagnostics provides diagnostic insights to improve health outcomes and serves a significant portion of the U.S. population [5] - The company collaborates with healthcare providers to enhance laboratory testing experiences and health management [6][7]

Core Insights - Quest Diagnostics reported a strong second quarter for 2025, with revenues increasing by 15.2% year-over-year, driven by both organic growth and acquisitions [2][6] - The company raised its full-year guidance for 2025 based on positive performance trends and increased demand for its clinical solutions [2][3] Financial Performance - Net revenues for the second quarter reached $2.76 billion, up from $2.40 billion in 2024, marking a 15.2% increase [2][6] - Diagnostic Information Services revenues also grew by 15.7% to $2.70 billion compared to $2.33 billion in the previous year [2][6] - Adjusted diluted EPS for the quarter was $2.62, reflecting an 11.5% increase from $2.35 in 2024 [2][6] - Operating income rose to $438 million, a 23.3% increase from $355 million in the same quarter last year [2][6] Operational Metrics - Requisition volume increased by 16.3%, while organic requisition volume grew by 2.1% [2][6] - Cash provided by operations for the first half of 2025 was $858 million, up 67.1% from $514 million in 2024 [2][6] Updated Guidance - The updated guidance for full-year 2025 includes net revenues projected between $10.80 billion and $10.92 billion, an increase of 9.4% to 10.6% [3] - Reported diluted EPS is now expected to be between $8.60 and $8.80, while adjusted diluted EPS is forecasted to be between $9.63 and $9.83 [3][6]

Core Viewpoint - Quest Diagnostics Inc. reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $2.21, exceeding estimates and showing year-over-year growth [1][2][8] Financial Performance - Adjusted EPS of $2.21 beat the Zacks Consensus Estimate by 2.8% and increased by 8.3% compared to the previous year [1] - GAAP EPS was $1.94, reflecting a 12.8% increase from the same quarter last year [2] - Revenues rose 12.1% year over year to $2.65 billion, surpassing the Zacks Consensus Estimate by 1.5% [3] - Diagnostic Information Services revenues increased by 12.7% year over year to $2.59 billion, exceeding projections [3] - Volumes measured by requisitions were up 12.5% year over year, with revenue per requisition increasing by 0.3% [4] Margin and Cost Analysis - Cost of services was $1.79 billion, up 12.2% year over year, while gross profit reached $863 million, an 11.9% increase [5] - Gross margin stood at 32.5%, nearly unchanged from the previous year [5] - SG&A expenses were $476 million, an 8.1% increase from the first quarter of 2024 [5] - Adjusted operating margin improved by 60 basis points year over year to 14.6% [5] Liquidity and Financial Health - Cash and cash equivalents at the end of Q1 2025 were $188 million, down from $549 million at the end of Q4 2024 [6] - Cumulative net cash from operating activities was $314 million, compared to $154 million at the same time last year [6] - The company has a five-year annualized dividend growth rate of 7.17% [6] 2025 Guidance - Full-year 2025 revenue outlook is reaffirmed at $10.70 billion to $10.85 billion, indicating a year-over-year increase of 8.4% to 9.9% [7] - Adjusted EPS guidance remains unchanged at $9.55 to $9.80, with the Zacks Consensus Estimate at $9.68 [7] Market Reaction and Outlook - Following the earnings report, DGX shares gained nearly 6.7% in pre-market trading [2] - The growth in revenue was attributed to a rebound in demand, contributions from acquisitions, and expanded health plan access [8][9]

Core Insights - Quest Diagnostics reported strong revenue growth of approximately 12% in Q1 2025, driven by demand recovery and contributions from acquisitions [2][7] - The company reaffirmed its revenue and adjusted EPS guidance for the full year 2025 [2] Financial Performance - Net revenues for Q1 2025 were $2.652 billion, up from $2.366 billion in Q1 2024, representing a 12.1% increase [2][12] - Diagnostic Information Services revenues increased by 12.7% to $2.589 billion [2][12] - Operating income rose to $346 million, a 15.4% increase from $300 million in the previous year [2][12] - Net income attributable to Quest Diagnostics was $220 million, up 13.2% from $194 million [2][12] - Diluted EPS for Q1 2025 was $1.94, reflecting a 12.8% increase from $1.72 in Q1 2024 [2][12] Operational Metrics - Requisition volume increased by 12.4%, while organic requisition volume decreased by 0.9% [2] - Revenue per requisition saw a slight increase of 0.3% [2] Updated Guidance for 2025 - The updated guidance for net revenues is projected between $10.70 billion and $10.85 billion, indicating an increase of 8.4% to 9.9% [3] - Reported diluted EPS is expected to range from $8.62 to $8.87, while adjusted diluted EPS remains between $9.55 and $9.80 [3][7] - Cash provided by operations is anticipated to be approximately $1.5 billion, with capital expenditures around $500 million [3] Cash Flow and Capital Expenditures - Cash provided by operations in Q1 2025 was $314 million, a significant increase of 103.4% from $154 million in Q1 2024 [2][16] - Capital expenditures for the quarter were $117 million, up 11.9% from $104 million [2][16] Balance Sheet Highlights - As of March 31, 2025, total assets were $15.797 billion, down from $16.153 billion at the end of 2024 [14] - Current liabilities decreased to $1.441 billion from $2.169 billion [14] - Total stockholders' equity increased to $6.962 billion from $6.813 billion [14]